In a phase I clinical trial, 23 R/R MM patients received BCMA/CD38 bispecific CAR-T cells, and 87% of them achieved clinical a response and 52% of them achieved complete response (CR) with a median follow-up of 9.0 months (30). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.